| Date | Time | Source | Headline | Symbol | Company |
| 08/21/2024 | 8:12AM | IH Market News | Walmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest News | NYSE:JNJ | Johnson and Johnson |
| 08/20/2024 | 7:30AM | Business Wire | Johnson & Johnson to Acquire V-Wave | NYSE:JNJ | Johnson and Johnson |
| 08/20/2024 | 7:00AM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer | NYSE:JNJ | Johnson and Johnson |
| 08/15/2024 | 6:05AM | IH Market News | Google Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova | NYSE:JNJ | Johnson and Johnson |
| 08/15/2024 | 6:05AM | IH Market News | Google Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova | NYSE:JNJ | Johnson and Johnson |
| 08/13/2024 | 5:43AM | IH Market News | Dell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and More | NYSE:JNJ | Johnson and Johnson |
| 08/09/2024 | 4:35PM | Edgar (US Regulatory) | Form 13F-HR - Quarterly report filed by institutional managers, Holdings | NYSE:JNJ | Johnson and Johnson |
| 08/07/2024 | 5:00PM | PR Newswire (US) | Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine | NYSE:JNJ | Johnson and Johnson |
| 07/30/2024 | 9:06PM | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NYSE:JNJ | Johnson and Johnson |
| 07/30/2024 | 6:42PM | PR Newswire (US) | DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible | NYSE:JNJ | Johnson and Johnson |
| 07/30/2024 | 6:00AM | IH Market News | Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots | NYSE:JNJ | Johnson and Johnson |
| 07/29/2024 | 4:00PM | Business Wire | Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference | NYSE:JNJ | Johnson and Johnson |
| 07/26/2024 | 9:38AM | Business Wire | Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan | NYSE:JNJ | Johnson and Johnson |
| 07/26/2024 | 9:05AM | Business Wire | FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan | NYSE:JNJ | Johnson and Johnson |
| 07/26/2024 | 6:07AM | IH Market News | Alphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in China | NYSE:JNJ | Johnson and Johnson |
| 07/25/2024 | 4:02PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:JNJ | Johnson and Johnson |
| 07/23/2024 | 4:00PM | Business Wire | Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NYSE:JNJ | Johnson and Johnson |
| 07/22/2024 | 11:59AM | Business Wire | Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan | NYSE:JNJ | Johnson and Johnson |
| 07/22/2024 | 8:00AM | PR Newswire (US) | Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression | NYSE:JNJ | Johnson and Johnson |
| 07/17/2024 | 8:14AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
| 07/17/2024 | 6:30AM | IH Market News | Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop | NYSE:JNJ | Johnson and Johnson |
| 07/17/2024 | 6:28AM | IH Market News | Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates | NYSE:JNJ | Johnson and Johnson |
| 07/17/2024 | 6:25AM | Business Wire | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 | NYSE:JNJ | Johnson and Johnson |
| 07/17/2024 | 6:20AM | Business Wire | Johnson & Johnson reports Q2 2024 results | NYSE:JNJ | Johnson and Johnson |
| 07/11/2024 | 7:30AM | Business Wire | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26 | NYSE:JNJ | Johnson and Johnson |
| 07/09/2024 | 5:48PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
| 07/03/2024 | 8:00AM | PR Newswire (Canada) | Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | NYSE:JNJ | Johnson and Johnson |
| 07/03/2024 | 8:00AM | PR Newswire (Canada) | Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules p | NYSE:JNJ | Johnson and Johnson |
| 07/02/2024 | 7:30AM | PR Newswire (US) | CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study | NYSE:JNJ | Johnson and Johnson |
| 06/28/2024 | 11:30AM | PR Newswire (US) | Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients | NYSE:JNJ | Johnson and Johnson |